학술논문
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8)
Document Type
Erratum
Author
Feigin, A.; Evans, E.E.; Fisher, T.L.; Leonard, J.E.; Smith, E.S.; Reader, A.; Mishra, V.; Zauderer, M.; Manber, R.; Walters, K.A.; Kowarski, L.; Oakes, D.; Kieburtz, K.D.; Barbano, R.; Siemers, E.; Kayson, E.; Goldstein, J.; Marder, K.; Dayalu, P.; Rosas, H.D.; Kostyk, S.; Kamholz, J.; Racette, B.; Bang, J.; Claassen, D.; McDonell, K.; Factor, S.; Walker, F.; Goas, C.; Wojcieszek, J.; Raymond, L.A.; Corey-Bloom, J.; Sung, V.; Dean, M.; Geshwind, M.; Nelson, A.; Frank, S.; LaFaver, K.; Duker, A.; Elmer, L.; Samii, A.; Lin, Y.-H.; Chouinard, S.; Seeberger, L.; Scott, B.; Boyd, J.; McFarland, N.; Stimming, E.F.; Suchowersky, O.; Testa, C.; Anderson, K.
Source
In: Nature Medicine . (Nature Medicine, February 2024, 30(2):606)
Subject
Language
English
ISSN
1546170X
10788956
10788956